107 related articles for article (PubMed ID: 20183444)
1. Estimation of multiple response rates in phase II clinical trials with missing observations.
Chang M
J Biopharm Stat; 2009 Sep; 19(5):791-802. PubMed ID: 20183444
[TBL] [Abstract][Full Text] [Related]
2. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.
Guo HY; Liu A
J Biopharm Stat; 2005; 15(5):773-81. PubMed ID: 16078384
[TBL] [Abstract][Full Text] [Related]
3. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
4. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
5. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
Baek I; Zhu W; Wu X; Wong WK
J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
[TBL] [Abstract][Full Text] [Related]
6. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
Hudgens MG
Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
[TBL] [Abstract][Full Text] [Related]
7. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
Liu A; Wu C; Yu KF; Gehan E
Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
[TBL] [Abstract][Full Text] [Related]
8. Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.
Song JX
Pharm Stat; 2006; 5(4):295-304. PubMed ID: 17128429
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the risk difference under a noncompliance randomized clinical trial with missing outcomes.
Lui KJ
J Biopharm Stat; 2008; 18(2):273-92. PubMed ID: 18327721
[TBL] [Abstract][Full Text] [Related]
10. Interval estimation of binomial proportion in clinical trials with a two-stage design.
Tsai WY; Chi Y; Chen CM
Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
[TBL] [Abstract][Full Text] [Related]
11. P-value calculation for multistage phase II cancer clinical trials.
Jung SH; Owzar K; George SL; Lee T
J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978
[TBL] [Abstract][Full Text] [Related]
12. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
13. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
14. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
Hutson AD
Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
[TBL] [Abstract][Full Text] [Related]
15. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
16. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
17. Application of pattern-mixture models to outcomes that are potentially missing not at random using pseudo maximum likelihood estimation.
Shen C; Weissfeld L
Biostatistics; 2005 Apr; 6(2):333-47. PubMed ID: 15772110
[TBL] [Abstract][Full Text] [Related]
18. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
19. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
Siddiqui O; Hung HM; O'Neill R
J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
[TBL] [Abstract][Full Text] [Related]
20. Missing not at random models for masked clinical trials with dropouts.
Kang S; Little RJ; Kaciroti N
Clin Trials; 2015 Apr; 12(2):139-48. PubMed ID: 25627429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
